DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
Purpose
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
Condition
- Cardiac Surgery
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female, at least 18 years of age 2. Undergoing CPB surgery with at least one risk factor for post-surgical bleeding including: 1. All re-operative cardiac procedures. 2. Expected bypass > 120 minutes. 3. Any combined cardiac surgery procedures (e.g. multiple valve, valve/CABG). 4. Any procedure that in the estimation of the surgical attending, has a high likelihood of receiving platelets 3. Ability to comprehend and willingness to sign informed consent. 4. If female of childbearing potential, have a negative pregnancy test on the day of the surgery and prior to the surgery agrees to use a method of highly effective birth control from the time of consent through the end of the safety follow-up period (Day 6 or discharge from hospital, whichever is earlier). Note: women must have been surgically sterilized [bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) or postmenopausal (≥50 years of age and continuous amenorrhea for 24 months) to be considered non-childbearing potential.
Exclusion Criteria
Subjects meeting any of the following criteria will be excluded from the study: 1. Undergoing any of the following surgical procedures: 1. Coronary artery bypass surgery alone 2. Implantation of ventricular assist device 3. Thoracoabdominal aortic aneurysm repair 2. Known or suspected pregnancy or breastfeeding 3. History of any major unprovoked thrombotic events 4. History of heparin-inducted thrombocytopenia 5. Active infection treated with antibiotics 6. Refuse transfusion of blood products for religious or other reasons 7. Previous enrollment in this study 8. Immune thrombocytopenic purpura 9. Known allergy to DMSO 10. In the judgement of the investigator, is not a good candidate for the study
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Randomized, parallel group, active comparator-controlled trial to evaluate the noninferiority or superiority of CPP with LSP in controlling blood loss in patients undergoing CPB surgery.
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Cryopreserved platelets |
Cryopreserved platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal |
|
|
Active Comparator Liquid stored platelets |
Liquid stored platelets to be given intraoperatively or post operatively up to 3 units post-heparin reversal |
|
Recruiting Locations
More Details
- Status
- Recruiting
- Sponsor
- Cellphire Therapeutics, Inc.
Detailed Description
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery. Patients planning to undergo Cardiopulmonary Bypass Surgery with risk factors for significant bleeding post-surgery will be approached. Subjects will be randomized in a 1:1 ratio to receive either Cryopreserved Platelets or Liquid Stored Platelets. Eligible subjects will undergo Cardiopulmonary Bypass Surgery and at the completion of bypass and heparin reversal subjects will likely be assessed for eligibility before coming off bypass. Study platelets will be given either intraoperatively after heparin reversal and return of active clotting time (ACT) to < 140 sec or post operatively (after chest closure). A single interim analysis is planned after 150 subjects are treated (75 in each treatment arm) to assess whether the study can be stopped for overwhelming efficacy or if an increase in sample size is warranted to maintain desired conditional power.